Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus temozolomide with radiation in newly diagnosed unmethylated MGMT glioblastoma
NL-OMON47552Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in glioblastoma (GBM) comparing Nivolumab + radiation therapy with Temozolomide + radiation therapy (2 arms). Primary endpoint: Overall survival. Started Jul 2016; status: active, not recruiting.
02
Drugs
nivolumabtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON47552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47552.